Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070447 · ClinicalTrials.gov registry record · Phase 2
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
A Phase 2 study of Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00070447 is a Phase 2 study of Lymphoma that has completed, run by National Cancer Institute (NCI). The trial reports 20 study locations across 9 states.
The verdict
NCT00070447, a Phase 2 study of Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as prednisone, cyclophosphamide, doxorubicin, and vincristine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab and combination chemotherapy together with yttrium Y 90 ibritumomab tiuxetan works in treating patients with previously untreated mantle cell lymphoma.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG doxorubicin hydrochloride
- DRUG vincristine sulfate
Study Locations (20)
Illinois
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- CCOP - Central Illinois - Decatur
- CCOP - Evanston - Evanston
- CCOP - Illinois Oncology Research Association - Peoria
- Swedish-American Regional Cancer Center - Rockford
Florida
- Veterans Affairs Medical Center - Gainesville - Gainesville
- Veterans Affairs Medical Center - Miami - Miami
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
- Veterans Affairs Medical Center - Tampa (Haley) - Tampa
California
- City of Hope Comprehensive Cancer Center - Duarte
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Stanford Cancer Center at Stanford University Medical Center - Stanford
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur
Alabama
- Comprehensive Cancer Center at University of Alabama at Birmingham - Birmingham
Arizona
- CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale
Colorado
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
Delaware
- CCOP - Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070447
The ClinicalTrials.gov registry entry for NCT00070447 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT00070447 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00070447 about?
NCT00070447 is a clinical study titled "Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma". RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as prednisone, cyclophosphamide, doxorubicin...
What is the current status of trial NCT00070447?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-11. Estimated completion is 2006-06.
What conditions does trial NCT00070447 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00070447?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), rituximab (BIOLOGICAL), doxorubicin hydrochloride (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00070447?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070447 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.